"Having a clear strategy makes it easy for Amneal to capitalize on unexpected opportunities. We know exactly where it is we want the company to be, and we aren't afraid to take action when the right opportunity presents itself."
Chirag Patel
President

Featured Products


  • Nizatidine Oral Solution
  • Demeclocycline Hydrochloride
  • Benazepril HCI Tablets
  • Tramadol HCI & Acetaminophen Tablets
  • Lorazepam Oral Concentrate
  • Spironolactone Tablets
  • Indomethacin ER Capsules
  • Promethazine HCl Tablets
  • Venlafaxine HCl Tablets
  • Levetiracetam Oral Solution
  • Nitrofurantoin Oral Suspension
  • Meclizine Hydrochloride Tablets
  • Ondansetron Oral Solution
  • Risperidone Oral Solution
  • Felbamate Tablets
  • Fluocinolone Acetonide Oil
  • Felbamate Oral

A Consumer's Guide to Generic Drugs


What Does THAT Mean?



Our Incredible Journey

Our founders established Amneal Pharmaceuticals in June 2002. Shortly thereafter, we picked up the pace and have been making things happen ever since. Take a highlighted look at how much we've accomplished in just a few short years; think of how much more we have in store. That said, check back soon for another exciting installment in our exhilarating chronicle.


June 2002 Amneal is born. Our headquarters, oral solids production and R&D plant opens in Paterson, New Jersey, initially manufacturing OTC products.
July 2005 We file our first ANDA (Benzonatate 100/200 mg. capsules) as Amneal Pharmaceuticals.
July 2005 Amneal secures a long-term financial partner ensuring strategic growth and continued, uncompromising quality.
August 2005 Amneal starts manufacturing its first Rx product (Folic Acid 1mg tablets).
July 2006 The first ANDA prepared and submitted by Amneal is approved (Metformin 500/850/1000mg tablets).
January 2007 Amneal files one of the first ANDAs with the US FDA using the eCTD / QbR / QOS format (Bethanechol 5/10/25/50mg tablets).
June 2007 We launch our Amneal label and go directly to the market via our acquisition of Akyma, a Kentucky-based pharmaceuticals sales and distribution company.
August 2007 Amneal completes a joint venture with Indoco Remedies of India to develop, market and distribute ophthalmic Rx products for the U.S. marketplace.
October 2007 We acquire all assets related to five generic drugs divested by Merck kGa to enable their acquisition by Mylan.
November 2007 Amneal's first eCTD / QbR / QOS-filed ANDA (Bethanechol tablets) is approved just 10 months and 10 days after submission.
December 2007 We acquire a liquid Rx manufacturing/R&D plant in Branchburg, New Jersey, along with multiple ANDAs and product development IP from KVD.
September 2008 Cardinal Health names Amneal VP of Sales, Stephen Rutledge, Trade Representative of the Year.
March 2008 Amneal's product development pipeline expands to 62 molecules.
April 2008 We announce our agreement to acquire substantially all assets of Interpharm Holdings, Inc. of Hauppauge, New York.
May 2008 Sweet 16! We celebrate our 16th FDA ANDA approval including two using eCTD / QbR / QOS submitted applications.
June 2008 Amneal welcomes another group to the family as our purchase of the Interpharm assets closes on June 23rd, including over 240,000 sq ft of manufacturing/R&D capacity in two superior quality plants.
September 2008 We launch our first liquid Rx product, Ranitidine HCl Syrup, manufactured at the Branchburg, New Jersey plant.
October 2008 We become the industry's first company to directly upload ANDAs to the FDA, server to server.
December 2008 Amneal celebrates the grand opening of our 75,000 sq ft R&D Centre, Amneal India.
March 2009 Our ANDA applications using eCTD / QbR / QOS now number 21 and counting-7 of which have already been approved. We have our second liquid ANDA approved for Prednisolone. Our ANDAs filed via server-to-server upload reach 10.
June 2009 Amneal introduces Alprazolam ER and Benazepril HCI tablets—each in four different strengths—adding to our increasingly sophisticated line a modified release controlled substance.
July 2009 IMS Study shows Amneal Pharmaceuticals as the 12th largest generics supplier in number of prescriptions dispensed. This same study remarks on the amazing 114% year-over-year growth Amneal has achieved.
September 2009 AmerisourceBergen recognizes Amneal as 2009 Generic Supplier of the Year - Under $50 Million. Our National Accounts Manager, Dave Hardin, is a Finalist for Generic Supplier Sales Representative of the Year.
November 2009 Cardinal presents Amneal with its 2009 Supplier Quality Award in recognition of our outstanding quality performance.
January 2010 IMS lists Amneal as the 10th largest generics supplier in its latest study nearing us even closer to our goal of falling within the top 5.
April 2010 National Account Manager, June Ray Parker, accepts the Smith Drug 2010 Generic Vendor of the Year award for Amneal Pharmaceuticals.
May 2010 McKesson honors Amneal with its Best Emerging Supplier, One Stop Sales Less Than $100 Million award.
June 2010 Amneal wins the HDMA 2010 DIANA award for Generic Product Manufacturer with Sales to Healthcare Distributors of Less Than $100 Million.
June 2010 IMS lists Amneal as the 9th largest generics manufacturer based on number of unbranded prescriptions dispensed.
September 2010 Amneal opens up a new, consolidated Distribution and Sales Logistics center in Glasgow, Kentucky.
October 2010 Amneal acquires a state-of-the-art R&D and manufacturing plant in Piscataway, New Jersey allowing further expansion into new technologies and complex, niche products.
December 2010 Amneal now appears as the 8th largest generics firm in the US according to IMS data.